CD274 and melanoma: An initial phase I study on the use of nivolumab, one of the PD‐1 inhibitors, supported a potential role for assessment of PD‐L1 expression on tumor cells in patients with several types of solid tumor including melanoma, NSCLC, renal cell carcinoma, and colorectal cancer (CRC).12